Reply

Jan 16, 2017 by in OPHTHALMOLOGY Comments Off on Reply

Dr Garudadri and associates raise several issues. As described in our baseline and outcomes paper, we anticipated greater dropouts in the brimonidine arm, thus randomizing more patients to brimonidine than…

read more

Reporting Visual Acuities

Jan 16, 2017 by in OPHTHALMOLOGY Comments Off on Reporting Visual Acuities

The AJO encourages authors to report the visual acuity in the manuscript using the same nomenclature that was used in gathering the data provided they were recorded in one of…

read more

Pars Plana Vitrectomy, Fluocinolone Acetonide Implantation, and Silicone Oil Infusion for the Treatment of Chronic, Refractory Uveitic Hypotony

Jan 16, 2017 by in OPHTHALMOLOGY Comments Off on Pars Plana Vitrectomy, Fluocinolone Acetonide Implantation, and Silicone Oil Infusion for the Treatment of Chronic, Refractory Uveitic Hypotony

Purpose To assess the feasibility and outcomes of combining fluocinolone acetonide sustained drug delivery implant insertion, pars plana vitrectomy, and silicone oil infusion to treat patients with chronic, refractory ocular…

read more

Continuous Progression of Tubercular Serpiginous-like Choroiditis After Initiating Antituberculosis Treatment

Jan 16, 2017 by in OPHTHALMOLOGY Comments Off on Continuous Progression of Tubercular Serpiginous-like Choroiditis After Initiating Antituberculosis Treatment

Purpose To describe the frequency, risk factors, management, and outcome of eyes with tubercular serpiginous-like choroiditis showing continued progression following initiation of antituberculosis treatment. Design Retrospective, comparative, interventional case series….

read more

Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension

Jan 16, 2017 by in OPHTHALMOLOGY Comments Off on Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension

Purpose To evaluate the ocular hypotensive efficacy of 0.05%, 0.1% and 0.25% AR-12286 Ophthalmic Solutions in patients diagnosed with ocular hypertension or glaucoma. Design Parallel comparison, vehicle-controlled, double-masked, 3-week randomized…

read more
Get Clinical Tree app for offline access